Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163011 | 0.89 | PLAU (0.55) | DGAT1SIRT2PLAUDEGS1MEN1 | |
| SCHEMBL158827 | 0.82 | PTPN1 (0.51) | NR1H4PTGDR2DEGS1 | |
| SCHEMBL161479 | 0.81 | NR1H4 (0.61) | DGAT1NR1H4PTGDR2 | |
| SCHEMBL162225 | 0.80 | SMN1; SMN2 (0.54) | NR1H4MEN1KMT2ARAB9AKDM4E | |
| SCHEMBL158818 | 0.78 | TRPV1 (0.51) | DGAT1NR1H4NPC1RAB9AKDM4E | |
| SCHEMBL26885217 | 0.76 | PTPN1 (0.73) | DGAT1NR1H4PLAUDEGS1MEN1 | |
| SCHEMBL162491 | 0.76 | MEN1 (0.43) | NR1H4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL162665 | 0.76 | NR1H4 (0.62) | DGAT1NR1H4PTGDR2 | |
| SCHEMBL160613 | 0.75 | PTPN1 (0.50) | DGAT1NR1H4DEGS1 | |
| SCHEMBL26885220 | 0.74 | DEGS1 (0.79) | DGAT1NR1H4PLAUDEGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885NR1H4 445/4885SIRT2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.